US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

CRVS Corvus Pharmaceuticals Inc

6.33

0.00 (0.00%)

Pre Mercado

Última actualización: 03:01:41

Retrasado por 15 minutos

Form EFFECT - Notice of Effectiveness

Corvus Pharmaceuticals (NASDAQ:CRVS)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024

Haga Click aquí para más Gráficas Corvus Pharmaceuticals.

Corvus Pharmaceuticals (NASDAQ:CRVS)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024

Haga Click aquí para más Gráficas Corvus Pharmaceuticals.

Noticias sobre Corvus Pharmaceuticals Inc CRVS

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Martes 10 de Septiembre 2024 (1 mes hace) • GlobeNewswire Inc.

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Martes 3 de Septiembre 2024 (1 mes hace) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Jueves 15 de Agosto 2024 (2 meses hace) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Martes 6 de Agosto 2024 (2 meses hace) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Martes 6 de Agosto 2024 (2 meses hace) • Edgar (US Regulatory)

Form 8-K - Current report
Martes 6 de Agosto 2024 (2 meses hace) • Edgar (US Regulatory)

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
Martes 6 de Agosto 2024 (2 meses hace) • GlobeNewswire Inc.

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Jueves 1 de Agosto 2024 (2 meses hace) • GlobeNewswire Inc.

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024
Miércoles 31 de Julio 2024 (2 meses hace) • GlobeNewswire Inc.

Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases
Jueves 25 de Julio 2024 (3 meses hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 17 de Junio 2024 (4 meses hace) • Edgar (US Regulatory)

Form 8-K - Current report
Viernes 14 de Junio 2024 (4 meses hace) • Edgar (US Regulatory)

Más de Corvus Pharmaceuticals Inc Artículos de Noticias

Bank of America

BNP Paribas (QX)

Verizon Communications

American Express

Health Care Select Sector

US Dollar vs MXN

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones